Dexcel Ltd.
Or-Akiva, IL· latest recorded location
Dexcel Ltd. is named on 8 US grants and 8 published applications in this corpus. Its most frequent classification is A61K (Medicines and medical preparations).
- Granted patents
- 8
- Published applications
- 8
- Inventors
- 9
- Granted in 2026 so far
- 0
- Most recent grant
- 16 Mar 2021
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2006 | 1 | 1 |
| 2007 | 1 | 2 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 1 | 1 |
| 2011 | 0 | 0 |
| 2012 | 1 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 1 | 0 |
| 2016 | 0 | 1 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 1 | 2 |
| 2020 | 0 | 1 |
| 2021 | 2 | 0 |
By publication year.
Technology areas
Share of 16 documents
Recent patents
- Celecoxib and amlodipine formulation and method of making the same16 Mar 2021US 10,945,960 B2
- Celecoxib and amlodipine formulation and method of making the same23 Feb 2021US 10,925,835 B2
- Celecoxib and amlodipine formulation and method of making the same16 Jul 2019US 10,350,171 B2
- Stable benzimidazole formulation5 May 2015US 9,023,391 B2
- Extended release venlafaxine tablet formulation31 Jan 2012US 8,105,627 B2
- Celecoxib and amlodipine formulation and method of making the same17 Dec 2020US 2020/0390713 A1
- Celecoxib and amlodipine formulation and method of making the same19 Sep 2019US 2019/0282507 A1
- Celecoxib and amlodipine formulation and method of making the same10 Jan 2019US 2019/0008777 A1
- Stable benzimidazole formulation28 Apr 2016US 2016/0113878 A1
- Process for forming solid oral dosage forms of angiotensin ii receptor antagonists4 Nov 2010US 2010/0278909 A1
Most cited
By later US patents